

Our Ref: 032/2020
January 2020

Re: Your request made under the Freedom of Information Act 2000

I have a Freedom of Information request regarding biologics and biosimilar prescribing in dermatology.

Could you please provide me with the following numbers of patients treated in the last 12 months with the following drugs:

Adalimumab [Amgevita]
Adalimumab [Hulio]
Adalimumab [Humira]
Adalimumab [Hyrimoz]
Adalimumab [Imraldi]
Apremilast [Otezla]
Brodalumab [Kyntheum]
Certolizumab [Cimzia]
Dimethyl fumarate [Skilarence]
Dupilumab [Dupixent]
Etanercept [Benepali]
Etanercept [Enbrel]
Etanercept [Erelzi]
Golimumab [Simponi]
Guselkumab [Tremfya]
Infliximab [Flixabi]
Infliximab [Inflectra]
Infliximab [Remicade]
Infliximab [Remsima]
Ixekizumab [Taltz]
Risankizumab [Skyrizi]
Secukinumab [Cosentyx]
Tildrakizumab [Ilumetri]
Tocilizumab [Ro Actemra]
Upadacitinib [Rinvoq]
Ustekinumab [Stelara]

If you are unable to provide the information above with specific reference to dermatology then please provide me with the numbers of patients treated in the last 12 months with the above drugs, regardless of disease/indication.

ADALIMUMAB (AMGEVITA) (Pre-filled Pen) 40 mg in 0.8mL Injection	22
ADALIMUMAB (HUMIRA) (Pre-filled Pen) 40 mg Injection	1
APREMILAST 30 mg Tablets	51
BRODALUMAB (Syringe) 210 mg in 1.5mL Injection	4
DIMETHYL FUMARATE (Skilarence) 120 mg Enteric Coated Tablets	25
DUPIUMAB (Pre-filled Syringe) 300 mg in 2mL Injection	2
ETANERCEPT (ENBREL) (Pre-filled Pen) 50 mg in 1mL Injection	1
GUSELKUMAB (Pre-filled Syringe) 100 mg in 1mL Injection	9
INFLIXIMAB (Remicade) 100 mg Intravenous Infusion	2
SECUKINUMAB (PEN) 150 mg in 1mL Injection	42
TILDRAKIZUMAB (Pre-filled Syringe) 100 mg in 1mL Injection	1
USTEKINUMAB (Pre-filled Syringe) 45 mg in 0.5mL Injection	10
USTEKINUMAB (Syringe) 90 mg in 1mL Injection	6